PRFX Fundamental Analysis - PAINREFORM LTD

Fundamental Rating

Overall PRFX gets a fundamental rating of 2 out of 10. We evaluated PRFX against 196 industry peers in the Pharmaceuticals industry. While PRFX seems to be doing ok healthwise, there are quite some concerns on its profitability. PRFX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PRFX had negative earnings in the past year.

In the past year PRFX has reported a negative cash flow from operations.

In the past 5 years PRFX always reported negative net income.

PRFX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of PRFX (-322.39%) is worse than 93.88% of its industry peers.

The Return On Equity of PRFX (-799.78%) is worse than 79.59% of its industry peers.

		Industry Rank	Sector Rank
ROA	-322.39%
ROE	-799.78%
ROIC	N/A

ROA(3y)-162.59%

ROA(5y)-109.71%

ROE(3y)-336.21%

ROE(5y)-214.62%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PRFX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, PRFX has more shares outstanding

Compared to 5 years ago, PRFX has more shares outstanding

PRFX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PRFX has an Altman-Z score of -27.02. This is a bad value and indicates that PRFX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -27.02, PRFX is doing worse than 85.71% of the companies in the same industry.

PRFX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-27.02

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.81 indicates that PRFX should not have too much problems paying its short term obligations.

PRFX has a worse Current ratio (1.81) than 63.27% of its industry peers.

PRFX has a Quick Ratio of 1.81. This is a normal value and indicates that PRFX is financially healthy and should not expect problems in meeting its short term obligations.

PRFX has a Quick ratio of 1.81. This is comparable to the rest of the industry: PRFX outperforms 42.86% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.81
Quick Ratio	1.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.23% over the past year.

EPS 1Y (TTM)81.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%53.95%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PRFX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.63% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y38.91%

EPS Next 2Y24.63%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PRFX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PRFX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PRFX's earnings are expected to grow with 24.63% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.63%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PRFX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PAINREFORM LTD

NASDAQ:PRFX (10/7/2025, 7:07:35 PM)

After market: 1.38 +0.02 (+1.47%)

1.36

-0.03 (-2.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-13 2025-08-13

Earnings (Next)N/A N/A

Inst Owners0.99%

Inst Owner Change0%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap2.73M

Analysts43.33

Price TargetN/A

Short Float %4.36%

Short Ratio0.02

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.5
P/tB	1.5
EV/EBITDA	N/A

EPS(TTM)-32.16

EYN/A

EPS(NY)-49.2

Fwd EYN/A

FCF(TTM)-6.29

FCFYN/A

OCF(TTM)-6.28

OCFYN/A

SpS0

BVpS0.91

TBVpS0.91

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-322.39%
ROE	-799.78%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-162.59%

ROA(5y)-109.71%

ROE(3y)-336.21%

ROE(5y)-214.62%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	81.25%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.81
Quick Ratio	1.81
Altman-Z	-27.02

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)63.75%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)81.23%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%53.95%

EPS Next Y38.91%

EPS Next 2Y24.63%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-53.1%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-88.91%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-88.97%

OCF growth 3YN/A

OCF growth 5YN/A

PAINREFORM LTD (PRFX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens